Patient-Centric Biospecimen Collection: Meeting Rare Disease Research Challenges

Photo Credit: CDC/ Dr. M. Candler

Patient-centric research starts with recognizing that patients are partners in research — not just passive sources of samples. This partnership means communicating clearly about research goals and incorporating patient priorities into research questions. It also means respecting participants’ time and contributions, and committing to share value back with the community through results and therapeutic progress.

For biospecimen collection specifically, patient-centricity shows up in practical, measurable ways:

• Logistical accessibility: participation opportunities regardless of geography, mobility limitations, or proximity to specialty centers.
• Reduced burden: convenient scheduling, home-based options, and integration with existing clinical care when feasible.
• Appropriate compensation: reflecting time and effort while reducing out-of-pocket costs and practical barriers.
• Clear informed consent: plain-language description of how samples/data will be used, privacy protections, and participant rights.
• Ongoing engagement: updates, feedback loops, and accessible study communications that build trust over time.

The Critical Role of Patient Advocacy Organizations

Patient advocacy organizations (PAGs) have become essential partners in rare disease biospecimen research. They connect researchers with patient communities, help shape research priorities, support recruitment, and make sure study design reflects real patient experience. Many PAGs also invest directly in research infrastructure — registries, natural history studies, and biobanking — especially for ultra-rare conditions where typical funding is hard to come by.

Advocacy partners bring expertise that meaningfully improves biospecimen study quality:

• Endpoint relevance: identifying symptoms and daily-life impacts that standard clinical measures can miss.
• Feasibility insight: surfacing barriers (travel, scheduling, caregiver demands, confidentiality concerns) before protocols are finalized.
• Community trust: improving recruitment via known, credible channels and clear expectations.
• Communication: helping translate complex study details into accessible language.

When PAGs get involved early — during protocol development and consent drafting — studies are more likely to hit enrollment goals. They also keep participants engaged and produce results that actually matter to patients and caregivers.

Integrating Patient-Reported Outcomes with Biospecimen Collection

Traditional biospecimen research often focuses on lab results (biomarkers, gene expression, metabolite patterns) without systematically capturing what patients actually experience. For many rare diseases, patient-reported outcomes (PROs) — pain, fatigue, function, GI symptoms, sleep, and quality of life — provide essential context for interpreting molecular findings.

Combining validated PRO tools with serial biospecimen collection lets researchers:

• Link molecular signatures to symptoms patients actually experience
• Validate whether biomarker changes correlate with meaningful outcomes
• Identify potential therapeutic targets for high-burden symptoms
• Improve endpoint selection for clinical trials (especially early-phase)

For example, correlating symptom trends with analytes measured in plasma, serum, and PBMCs can help reveal inflammatory, metabolic, or immunologic pathways tied to patient-relevant disease burden. This is especially useful in longitudinal designs.

Reducing Participation Burden Through Direct-to-Patient Collection

Geographic barriers are one of the most persistent obstacles in rare disease research. When protocols require participants to travel to academic centers, patients in rural areas, those with limited mobility, and families facing transportation or caregiver constraints may be left out. Since rare disease patients are already few and far between across the United States, these barriers can bias cohorts and make recruitment goals unreachable.

Direct-to-patient biospecimen collection solves this by bringing research to participants. Mobile phlebotomy teams can collect blood-based specimens (whole blood, plasma, serum, PBMCs) and other sample types (like urine) according to study protocols. This removes travel requirements and enables broader participation.

For pediatric populations, home-based collection can make a real difference, reducing disruption to family schedules and improving long-term retention. Home collection may also ease anxiety for participants who find clinical settings stressful.

Quality in direct-to-patient collection depends on rigorous SOPs, training, standardized kits, chain-of-custody, temperature control, and time-to-processing requirements matched to study needs. For studies that need specialized handling (like PBMC isolation windows), workflows must be designed to preserve sample integrity from collection through shipment to the lab.

Ethical Frameworks and Informed Consent

Ethical biospecimen research requires informed consent that clearly explains the research purpose, potential risks and benefits, data privacy protections, and participant rights. In rare disease studies where samples may be stored and reused, consent should clearly describe:

• Scope of current research use vs. future research use
• Governance for future access decisions
• Whether and how re-contact may occur
• Data sharing practices and residual re-identification risk

Privacy matters even more as detailed genomic annotation becomes more common. Genomic data and deep clinical phenotyping can raise the risk of re-identification. Security controls, de-identification practices, and access policies should be transparent and follow regulatory requirements.

Participant Compensation: Valuing Contributions and Reducing Barriers

Compensation should recognize that participation has real costs: time, effort, childcare needs, and potential lost wages. Ignoring these costs can shut out willing participants. Ethical compensation aims to reduce barriers without creating undue pressure to participate. IRBs and ethics committees weigh in based on study burden and how vulnerable the population is.

For direct-to-patient models, removing travel burden already cuts cost and stress. Compensation can then focus on participant time, effort, and any study-specific inconvenience.

Building Long-Term Research Relationships

Rare disease research increasingly benefits from ongoing engagement rather than one-time collections. Natural history studies, recall-on-demand repositories, and registry-linked biobanking enable longitudinal insight: within-person comparisons, treatment response patterns, and early biomarker discovery that cross-sectional designs often miss.

Direct-to-patient infrastructure supports these relationships by making repeat participation easier and less disruptive, improving retention in multi-year protocols.

Returning Results and Research Findings to Participants

Patient-centric biospecimen research includes a commitment to sharing study progress and findings with the community in accessible formats. While individual results may not always be clinically actionable, aggregate updates help participants see how their contribution is moving research forward.

When clinically relevant or sensitive findings are possible (like genetic variants with health implications), protocols should define how results will be returned. That includes clinical context, proper counseling, and participant preferences.

From Study Design to Receipt of Samples: Patient Partnership Throughout

True patient-centric biospecimen research brings patients in as partners from the initial study concept all the way through sharing results. Advocacy representatives can help shape research questions, identify meaningful endpoints, improve consent language, anticipate participation barriers, and support ongoing engagement.

Sanguine’s approach supports patient-centric rare disease research through direct-to-donor accessibility, integration of patient-reported outcomes, and rigorous operational quality from study design to receipt of samples. Our infrastructure is built to support diverse rare disease programs while prioritizing participant experience, ethical excellence, and reproducible specimen quality.

---

References

1. Rare Diseases Clinical Research Network. NIH Announces Funding to Establish and Strengthen Rare Disease Research Groups. Published October 29, 2024. Accessed December 10, 2024. NIH Announces Funding to Establish and Strengthen Rare Disease Research Groups
2. IQVIA. Unlocking Clinical and Commercial Success: How PAGs Power Rare Disease Innovation. Published August 2024. Accessed December 10, 2024. Unlocking Clinical and Commercial Success: How PAGs Power Rare Disease Innovation
3. BioMarin. Patient Community Engagement. Published 2024. Accessed December 10, 2024. Patient Community Engagement
4. Emerging roles and opportunities for rare disease patient advocacy groups. SAGE Journals. Published 2023. Accessed December 10, 2024. Emerging roles and opportunities for rare disease patient advocacy groups
5. NIH. PAR-25-438: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN). Published 2024. Accessed December 10, 2024. PAR-25-438: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
6. EveryLife Foundation for Rare Diseases. Valuing Rare Disease Treatments in Healthcare: Real Experience and Insights from Patients and Caregivers. Published January 2024. Accessed December 10, 2024. Valuing Rare Disease Treatments in Healthcare: Real Experience and Insights from Patients and Caregivers